Document is current
Any future updates will be listed below
-
Authors
Rodon, Jordi
Chaney, Marya
Cohen, Justine
Garyantes, Tina
Lin, Jessica
Lorusso, Patricia
Mita, Alain
Mita, Monica
Muller, Carolyn
Natale, Christopher
Orloff, Marlana
Papadopoulos, Kyriakos
Patel, Sapna
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04130516 at ClinicalTrials.govnct04130516 at ClinicalTrials.govDocuments that mention this clinical trial
759 Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2022-sitc2022.0759
627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
https://doi.org/10.1136/jitc-2023-sitc2023.0627
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9543
Ovariectomy-Induced Arterial Stiffening Differs From Vascular Aging and Is Reversed by GPER Activation
https://doi.org/10.1161/hypertensionaha.123.22024
Documents that mention this clinical trial
759 Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2022-sitc2022.0759
627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
https://doi.org/10.1136/jitc-2023-sitc2023.0627
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9543
Ovariectomy-Induced Arterial Stiffening Differs From Vascular Aging and Is Reversed by GPER Activation
https://doi.org/10.1161/hypertensionaha.123.22024
